|
Jul 23
|
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
|
|
Jul 16
|
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
|
|
Jul 8
|
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
|
|
Jun 29
|
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
|
|
Jun 26
|
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
|
|
Jun 25
|
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
|
|
Jun 24
|
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
|
|
Apr 15
|
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
|
|
Feb 24
|
Entera Bio to Participate in Upcoming Events
|
|
Feb 19
|
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
|
|
Oct 4
|
Are Medical Stocks Lagging Argenx (ARGX) This Year?
|
|
Aug 1
|
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
|
|
Jul 23
|
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
|
|
Jun 20
|
7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months
|
|
Jun 20
|
Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich
|
|
Jun 17
|
3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
|
|
May 15
|
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
|
|
May 13
|
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
|
|
May 10
|
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
|
|
Apr 30
|
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
|